Jeanelle Sheeder
Concepts (624)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contraception | 19 | 2024 | 161 | 6.870 |
Why?
| | Contraceptive Agents, Female | 26 | 2024 | 80 | 4.340 |
Why?
| | Family Planning Services | 12 | 2023 | 92 | 3.360 |
Why?
| | Contraception Behavior | 19 | 2024 | 102 | 3.280 |
Why?
| | Desogestrel | 22 | 2024 | 46 | 3.180 |
Why?
| | Contraceptive Agents | 7 | 2023 | 66 | 3.170 |
Why?
| | Pregnancy in Adolescence | 18 | 2024 | 83 | 3.050 |
Why?
| | Long-Acting Reversible Contraception | 9 | 2024 | 33 | 2.360 |
Why?
| | Pregnancy | 76 | 2024 | 6763 | 2.130 |
Why?
| | Abortion, Induced | 13 | 2024 | 105 | 2.020 |
Why?
| | Drug Implants | 20 | 2024 | 82 | 1.950 |
Why?
| | Prenatal Care | 9 | 2020 | 294 | 1.870 |
Why?
| | Hospitals, Religious | 5 | 2020 | 5 | 1.650 |
Why?
| | Adolescent Health Services | 4 | 2024 | 71 | 1.580 |
Why?
| | Counseling | 6 | 2020 | 391 | 1.520 |
Why?
| | Postpartum Period | 11 | 2024 | 340 | 1.500 |
Why?
| | Intrauterine Devices | 7 | 2019 | 31 | 1.490 |
Why?
| | Adolescent | 90 | 2024 | 21513 | 1.430 |
Why?
| | Female | 168 | 2024 | 73304 | 1.430 |
Why?
| | Gynecology | 10 | 2023 | 168 | 1.430 |
Why?
| | Young Adult | 67 | 2024 | 13209 | 1.350 |
Why?
| | Adolescent Behavior | 9 | 2015 | 530 | 1.350 |
Why?
| | Pregnancy Outcome | 8 | 2021 | 416 | 1.140 |
Why?
| | Reproductive Health | 4 | 2023 | 90 | 1.120 |
Why?
| | Catholicism | 5 | 2020 | 10 | 1.090 |
Why?
| | Chlamydia Infections | 3 | 2024 | 75 | 1.080 |
Why?
| | Endometrial Neoplasms | 10 | 2022 | 201 | 1.080 |
Why?
| | Humans | 185 | 2024 | 137585 | 1.080 |
Why?
| | Colorado | 35 | 2024 | 4565 | 1.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 11 | 2024 | 1329 | 0.990 |
Why?
| | Obstetrics | 7 | 2023 | 163 | 0.980 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2023 | 19 | 0.950 |
Why?
| | Postnatal Care | 3 | 2021 | 71 | 0.890 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 806 | 0.880 |
Why?
| | Trichomonas Infections | 1 | 2024 | 11 | 0.860 |
Why?
| | Trichomonas vaginalis | 1 | 2024 | 14 | 0.860 |
Why?
| | Adult | 89 | 2024 | 37929 | 0.850 |
Why?
| | Confidentiality | 1 | 2024 | 73 | 0.840 |
Why?
| | Sexual Behavior | 7 | 2022 | 485 | 0.820 |
Why?
| | Enoxaparin | 2 | 2020 | 63 | 0.800 |
Why?
| | Patient Satisfaction | 5 | 2023 | 660 | 0.800 |
Why?
| | Cross-Sectional Studies | 24 | 2024 | 5472 | 0.760 |
Why?
| | Religion and Medicine | 3 | 2020 | 31 | 0.750 |
Why?
| | Pyridones | 2 | 2020 | 168 | 0.750 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 161 | 0.740 |
Why?
| | Surveys and Questionnaires | 25 | 2024 | 5778 | 0.720 |
Why?
| | Ambulatory Care Facilities | 5 | 2024 | 232 | 0.690 |
Why?
| | Levonorgestrel | 4 | 2018 | 38 | 0.680 |
Why?
| | Pyrazoles | 2 | 2020 | 423 | 0.660 |
Why?
| | Parity | 5 | 2016 | 126 | 0.660 |
Why?
| | Group Processes | 2 | 2018 | 64 | 0.650 |
Why?
| | Mothers | 5 | 2022 | 754 | 0.650 |
Why?
| | Religion and Psychology | 1 | 2019 | 28 | 0.640 |
Why?
| | Hysterectomy | 6 | 2019 | 129 | 0.630 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 86 | 0.630 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 316 | 0.620 |
Why?
| | Pregnancy Rate | 2 | 2017 | 65 | 0.610 |
Why?
| | Intention | 5 | 2024 | 170 | 0.610 |
Why?
| | Community Health Services | 2 | 2023 | 227 | 0.600 |
Why?
| | Patient-Centered Care | 2 | 2021 | 530 | 0.600 |
Why?
| | Sex Offenses | 1 | 2022 | 196 | 0.600 |
Why?
| | Vulnerable Populations | 1 | 2020 | 163 | 0.590 |
Why?
| | Financial Support | 1 | 2018 | 22 | 0.590 |
Why?
| | Health Care Sector | 1 | 2018 | 25 | 0.580 |
Why?
| | Rural Health Services | 1 | 2019 | 128 | 0.580 |
Why?
| | Intrauterine Devices, Copper | 5 | 2018 | 7 | 0.580 |
Why?
| | Ovarian Neoplasms | 6 | 2020 | 565 | 0.580 |
Why?
| | Pregnancy, Unplanned | 3 | 2017 | 48 | 0.570 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 270 | 0.560 |
Why?
| | Prosthesis Implantation | 2 | 2017 | 153 | 0.550 |
Why?
| | Luteal Phase | 1 | 2017 | 45 | 0.520 |
Why?
| | Health Services Accessibility | 4 | 2024 | 986 | 0.520 |
Why?
| | Intrauterine Devices, Medicated | 6 | 2017 | 29 | 0.520 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 141 | 0.520 |
Why?
| | Chlamydia trachomatis | 3 | 2024 | 49 | 0.520 |
Why?
| | Delivery of Health Care | 2 | 2023 | 951 | 0.500 |
Why?
| | Retrospective Studies | 33 | 2024 | 15657 | 0.500 |
Why?
| | Parenting | 1 | 2020 | 310 | 0.490 |
Why?
| | Lacerations | 3 | 2022 | 35 | 0.490 |
Why?
| | Interprofessional Relations | 1 | 2018 | 283 | 0.480 |
Why?
| | Life Style | 4 | 2024 | 490 | 0.480 |
Why?
| | Depression, Postpartum | 3 | 2020 | 132 | 0.470 |
Why?
| | Group Structure | 1 | 2015 | 3 | 0.470 |
Why?
| | Guatemala | 3 | 2021 | 327 | 0.470 |
Why?
| | Perimenopause | 1 | 2015 | 63 | 0.460 |
Why?
| | Genital Neoplasms, Female | 4 | 2020 | 90 | 0.460 |
Why?
| | Risk | 2 | 2017 | 912 | 0.460 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 50 | 0.460 |
Why?
| | Fertility Preservation | 3 | 2023 | 49 | 0.450 |
Why?
| | Health Personnel | 1 | 2021 | 710 | 0.450 |
Why?
| | Uterus | 1 | 2015 | 215 | 0.440 |
Why?
| | Multicenter Studies as Topic | 1 | 2015 | 310 | 0.440 |
Why?
| | Patient Selection | 3 | 2015 | 696 | 0.430 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1477 | 0.430 |
Why?
| | Safety-net Providers | 1 | 2015 | 119 | 0.430 |
Why?
| | Maternal Age | 3 | 2018 | 129 | 0.420 |
Why?
| | Goals | 1 | 2014 | 170 | 0.390 |
Why?
| | Attitude to Health | 3 | 2020 | 439 | 0.390 |
Why?
| | Primary Health Care | 4 | 2023 | 1738 | 0.390 |
Why?
| | Choice Behavior | 3 | 2019 | 170 | 0.380 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 238 | 0.380 |
Why?
| | Estradiol | 1 | 2015 | 521 | 0.380 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2021 | 257 | 0.380 |
Why?
| | Mass Screening | 9 | 2023 | 1287 | 0.370 |
Why?
| | Middle Aged | 39 | 2022 | 33479 | 0.370 |
Why?
| | Internship and Residency | 6 | 2023 | 1147 | 0.370 |
Why?
| | Premature Birth | 1 | 2015 | 333 | 0.360 |
Why?
| | Gestational Age | 5 | 2024 | 910 | 0.360 |
Why?
| | Obstetric Labor Complications | 2 | 2022 | 34 | 0.350 |
Why?
| | Postoperative Complications | 9 | 2020 | 2654 | 0.350 |
Why?
| | Child | 19 | 2024 | 21935 | 0.350 |
Why?
| | Magnetoencephalography | 13 | 2000 | 149 | 0.330 |
Why?
| | Disclosure | 2 | 2022 | 113 | 0.330 |
Why?
| | Feasibility Studies | 7 | 2022 | 956 | 0.320 |
Why?
| | Functional Laterality | 11 | 2001 | 223 | 0.320 |
Why?
| | Health Behavior | 1 | 2015 | 762 | 0.320 |
Why?
| | Nurse Midwives | 2 | 2020 | 36 | 0.320 |
Why?
| | United States | 19 | 2021 | 14841 | 0.320 |
Why?
| | Lymph Nodes | 3 | 2018 | 491 | 0.310 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 130 | 0.310 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1171 | 0.310 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1289 | 0.310 |
Why?
| | Condoms | 3 | 2017 | 103 | 0.310 |
Why?
| | Birth Intervals | 2 | 2019 | 23 | 0.310 |
Why?
| | Evoked Potentials, Auditory | 10 | 2001 | 180 | 0.310 |
Why?
| | Communication | 3 | 2022 | 879 | 0.300 |
Why?
| | Intrauterine Device Expulsion | 3 | 2017 | 9 | 0.290 |
Why?
| | Male | 45 | 2024 | 67762 | 0.290 |
Why?
| | Patient Participation | 1 | 2012 | 420 | 0.280 |
Why?
| | Infant, Small for Gestational Age | 2 | 2019 | 92 | 0.280 |
Why?
| | Time Factors | 12 | 2024 | 6828 | 0.280 |
Why?
| | Sexual Partners | 3 | 2024 | 186 | 0.270 |
Why?
| | Attitude | 3 | 2019 | 259 | 0.270 |
Why?
| | Quality Improvement | 4 | 2024 | 1178 | 0.270 |
Why?
| | Women's Health | 2 | 2020 | 372 | 0.270 |
Why?
| | Prediabetic State | 2 | 2023 | 253 | 0.270 |
Why?
| | Cohort Studies | 11 | 2021 | 5742 | 0.260 |
Why?
| | Pregnancy Complications | 4 | 2019 | 527 | 0.260 |
Why?
| | Vaccination | 1 | 2015 | 1381 | 0.260 |
Why?
| | Uterine Cervicitis | 1 | 2006 | 8 | 0.260 |
Why?
| | Organizational Policy | 2 | 2019 | 84 | 0.250 |
Why?
| | Age Factors | 8 | 2016 | 3295 | 0.240 |
Why?
| | Perineum | 3 | 2022 | 32 | 0.240 |
Why?
| | Marijuana Use | 2 | 2019 | 206 | 0.240 |
Why?
| | Prospective Studies | 14 | 2022 | 7604 | 0.230 |
Why?
| | Aged, 80 and over | 11 | 2021 | 7635 | 0.230 |
Why?
| | Pregnancy Trimester, First | 4 | 2023 | 140 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2531 | 0.230 |
Why?
| | Gelatin | 2 | 2016 | 52 | 0.230 |
Why?
| | Depression | 4 | 2023 | 1397 | 0.230 |
Why?
| | Fetal Death | 2 | 2016 | 55 | 0.230 |
Why?
| | Laparotomy | 2 | 2015 | 109 | 0.230 |
Why?
| | Electronics, Medical | 1 | 2004 | 13 | 0.230 |
Why?
| | Weight Gain | 6 | 2021 | 519 | 0.220 |
Why?
| | Aged | 18 | 2021 | 23961 | 0.220 |
Why?
| | Legal Guardians | 1 | 2024 | 10 | 0.220 |
Why?
| | Database Management Systems | 1 | 2004 | 51 | 0.220 |
Why?
| | Clinical Competence | 3 | 2018 | 1118 | 0.220 |
Why?
| | Thrombin | 2 | 2016 | 152 | 0.220 |
Why?
| | Privacy | 1 | 2024 | 42 | 0.220 |
Why?
| | Contact Tracing | 1 | 2024 | 27 | 0.220 |
Why?
| | Aromatherapy | 1 | 2023 | 2 | 0.210 |
Why?
| | Pregnancy Trimester, Second | 4 | 2018 | 80 | 0.210 |
Why?
| | Scapula | 1 | 2024 | 46 | 0.210 |
Why?
| | Contraceptive Devices | 1 | 2023 | 3 | 0.210 |
Why?
| | Pain, Procedural | 1 | 2023 | 15 | 0.210 |
Why?
| | Telemedicine | 2 | 2023 | 862 | 0.210 |
Why?
| | Ethinyl Estradiol | 1 | 2023 | 16 | 0.210 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 591 | 0.210 |
Why?
| | Birth Weight | 1 | 2006 | 516 | 0.210 |
Why?
| | Social Support | 2 | 2020 | 618 | 0.210 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 306 | 0.200 |
Why?
| | Pediatricians | 1 | 2024 | 129 | 0.200 |
Why?
| | Fertility | 3 | 2023 | 160 | 0.200 |
Why?
| | Device Removal | 1 | 2024 | 136 | 0.200 |
Why?
| | Patient Health Questionnaire | 1 | 2023 | 37 | 0.200 |
Why?
| | House Calls | 2 | 2019 | 138 | 0.200 |
Why?
| | Decision Making | 4 | 2016 | 900 | 0.200 |
Why?
| | Physician's Role | 1 | 2024 | 211 | 0.200 |
Why?
| | Pain | 2 | 2018 | 756 | 0.200 |
Why?
| | Pediatrics | 2 | 2024 | 1101 | 0.200 |
Why?
| | Leuprolide | 1 | 2022 | 20 | 0.200 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 105 | 0.200 |
Why?
| | Semen | 1 | 2022 | 18 | 0.200 |
Why?
| | Patient Preference | 2 | 2015 | 191 | 0.190 |
Why?
| | Pregnancy Tests | 2 | 2017 | 9 | 0.190 |
Why?
| | Exercise | 3 | 2024 | 2057 | 0.190 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2021 | 37 | 0.180 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 26 | 0.180 |
Why?
| | Chorioamnionitis | 1 | 2021 | 42 | 0.180 |
Why?
| | Students, Medical | 2 | 2016 | 348 | 0.180 |
Why?
| | Pilot Projects | 4 | 2024 | 1710 | 0.180 |
Why?
| | Decision Support Techniques | 2 | 2020 | 421 | 0.170 |
Why?
| | Maternal-Child Health Services | 1 | 2020 | 12 | 0.170 |
Why?
| | beta Catenin | 2 | 2022 | 253 | 0.170 |
Why?
| | Self Report | 3 | 2021 | 827 | 0.170 |
Why?
| | Lymph Node Excision | 3 | 2018 | 171 | 0.170 |
Why?
| | Parturition | 2 | 2019 | 71 | 0.170 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 33 | 0.170 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 113 | 0.160 |
Why?
| | Magnetics | 2 | 1999 | 48 | 0.160 |
Why?
| | Patient Education as Topic | 3 | 2019 | 766 | 0.160 |
Why?
| | Accelerometry | 1 | 2021 | 103 | 0.160 |
Why?
| | Uterine Hemorrhage | 2 | 2021 | 37 | 0.160 |
Why?
| | Health Facilities | 1 | 2020 | 84 | 0.160 |
Why?
| | Home Health Nursing | 1 | 2019 | 12 | 0.160 |
Why?
| | Outpatients | 3 | 2023 | 396 | 0.160 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 13 | 0.160 |
Why?
| | Pharmacogenetics | 1 | 2021 | 180 | 0.160 |
Why?
| | Hysterectomy, Vaginal | 1 | 2019 | 5 | 0.160 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 283 | 0.160 |
Why?
| | Body Mass Index | 5 | 2024 | 2389 | 0.160 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2019 | 4 | 0.160 |
Why?
| | Cytochrome P450 Family 3 | 1 | 2019 | 3 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2017 | 66 | 0.160 |
Why?
| | Cues | 1 | 2022 | 314 | 0.160 |
Why?
| | Vaginosis, Bacterial | 1 | 2019 | 12 | 0.160 |
Why?
| | Medical Oncology | 2 | 2019 | 289 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2023 | 561 | 0.160 |
Why?
| | Transgender Persons | 1 | 2022 | 186 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2008 | 1208 | 0.150 |
Why?
| | Clothing | 1 | 2019 | 22 | 0.150 |
Why?
| | Hygiene | 1 | 2019 | 30 | 0.150 |
Why?
| | Cancer Pain | 1 | 2019 | 29 | 0.150 |
Why?
| | Neoplasm Staging | 6 | 2020 | 1389 | 0.150 |
Why?
| | Double-Blind Method | 5 | 2018 | 1993 | 0.150 |
Why?
| | Live Birth | 1 | 2019 | 66 | 0.150 |
Why?
| | Obesity | 5 | 2016 | 2992 | 0.150 |
Why?
| | Anesthesia, Inhalation | 1 | 2018 | 9 | 0.150 |
Why?
| | Anesthesia, Intravenous | 1 | 2018 | 16 | 0.150 |
Why?
| | Nitrous Oxide | 1 | 2018 | 33 | 0.150 |
Why?
| | Anesthetics, Intravenous | 1 | 2018 | 47 | 0.150 |
Why?
| | Treatment Outcome | 10 | 2020 | 10811 | 0.150 |
Why?
| | Physician Assistants | 1 | 2020 | 94 | 0.150 |
Why?
| | Databases, Factual | 3 | 2021 | 1357 | 0.150 |
Why?
| | Anesthetics, Inhalation | 1 | 2018 | 35 | 0.150 |
Why?
| | Models, Anatomic | 1 | 2019 | 93 | 0.150 |
Why?
| | Genitalia, Female | 1 | 2018 | 38 | 0.150 |
Why?
| | Databases as Topic | 2 | 2008 | 67 | 0.150 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 22 | 0.140 |
Why?
| | Progesterone | 1 | 2019 | 254 | 0.140 |
Why?
| | Ovariectomy | 2 | 2015 | 152 | 0.140 |
Why?
| | Off-Label Use | 1 | 2018 | 52 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2021 | 250 | 0.140 |
Why?
| | Oncologists | 1 | 2018 | 38 | 0.140 |
Why?
| | Nurse Practitioners | 1 | 2020 | 138 | 0.140 |
Why?
| | Culture | 1 | 2019 | 128 | 0.140 |
Why?
| | Logistic Models | 6 | 2024 | 2074 | 0.140 |
Why?
| | Risk-Taking | 2 | 2019 | 348 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2015 | 940 | 0.140 |
Why?
| | Psychometrics | 4 | 2009 | 720 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1692 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 103 | 0.140 |
Why?
| | Commerce | 1 | 2018 | 82 | 0.140 |
Why?
| | Sterilization, Reproductive | 1 | 2017 | 7 | 0.140 |
Why?
| | Hysteroscopy | 1 | 2017 | 12 | 0.140 |
Why?
| | Demyelinating Diseases | 1 | 1998 | 85 | 0.140 |
Why?
| | Quality of Health Care | 2 | 2021 | 642 | 0.130 |
Why?
| | Delivery, Obstetric | 4 | 2022 | 144 | 0.130 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 80 | 0.130 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 145 | 0.130 |
Why?
| | Salpingectomy | 2 | 2015 | 13 | 0.130 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 34 | 0.130 |
Why?
| | Surgeons | 2 | 2018 | 297 | 0.130 |
Why?
| | Abortion, Therapeutic | 1 | 2016 | 3 | 0.130 |
Why?
| | Infant, Newborn | 6 | 2021 | 6079 | 0.130 |
Why?
| | Brain Diseases | 1 | 1998 | 141 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 188 | 0.130 |
Why?
| | Dilatation and Curettage | 1 | 2016 | 11 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 660 | 0.130 |
Why?
| | Family | 1 | 2021 | 671 | 0.130 |
Why?
| | Incidence | 5 | 2019 | 2804 | 0.130 |
Why?
| | Ultrasonography | 2 | 2019 | 759 | 0.130 |
Why?
| | Pelvic Infection | 1 | 2016 | 4 | 0.130 |
Why?
| | Conflict of Interest | 1 | 2018 | 130 | 0.130 |
Why?
| | Bipolar Disorder | 1 | 1999 | 263 | 0.130 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 64 | 0.130 |
Why?
| | Minority Groups | 1 | 2018 | 266 | 0.130 |
Why?
| | Medical Marijuana | 1 | 2018 | 117 | 0.130 |
Why?
| | Follow-Up Studies | 8 | 2019 | 5131 | 0.130 |
Why?
| | Tissue Adhesives | 1 | 2016 | 19 | 0.130 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 117 | 0.120 |
Why?
| | Contraception, Postcoital | 1 | 2016 | 6 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2020 | 546 | 0.120 |
Why?
| | Cerebral Cortex | 1 | 1999 | 433 | 0.120 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 36 | 0.120 |
Why?
| | Pregnancy, Unwanted | 1 | 2015 | 14 | 0.120 |
Why?
| | Infant | 3 | 2023 | 9465 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 307 | 0.120 |
Why?
| | Internet | 2 | 2019 | 655 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 7 | 2001 | 3566 | 0.120 |
Why?
| | Risk Reduction Behavior | 2 | 2014 | 220 | 0.120 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 129 | 0.120 |
Why?
| | Patient Compliance | 2 | 2012 | 581 | 0.120 |
Why?
| | Placebos | 1 | 2015 | 199 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 664 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 611 | 0.120 |
Why?
| | Interpersonal Relations | 2 | 2017 | 397 | 0.120 |
Why?
| | Physician-Patient Relations | 2 | 2019 | 548 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 167 | 0.110 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 43 | 0.110 |
Why?
| | Hot Flashes | 1 | 2015 | 87 | 0.110 |
Why?
| | Curriculum | 3 | 2018 | 992 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 161 | 0.110 |
Why?
| | Papillomaviridae | 1 | 2015 | 125 | 0.110 |
Why?
| | Advanced Practice Nursing | 1 | 2015 | 39 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 654 | 0.110 |
Why?
| | Risk Factors | 10 | 2022 | 10388 | 0.110 |
Why?
| | Abdominal Abscess | 1 | 2014 | 27 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 181 | 0.110 |
Why?
| | Pandemics | 1 | 2023 | 1639 | 0.110 |
Why?
| | Immunization Schedule | 1 | 2015 | 197 | 0.110 |
Why?
| | Schizophrenia | 4 | 2000 | 439 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 342 | 0.110 |
Why?
| | Endometrium | 1 | 2014 | 58 | 0.110 |
Why?
| | Neoplasm Grading | 3 | 2022 | 307 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.110 |
Why?
| | Digoxin | 1 | 2013 | 31 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 329 | 0.100 |
Why?
| | Otolaryngology | 1 | 2015 | 96 | 0.100 |
Why?
| | Brain | 8 | 2001 | 2668 | 0.100 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2013 | 17 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 26 | 0.100 |
Why?
| | Robotics | 1 | 2014 | 94 | 0.100 |
Why?
| | Umbilical Cord | 1 | 2013 | 85 | 0.100 |
Why?
| | Peer Group | 1 | 2015 | 242 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2014 | 107 | 0.100 |
Why?
| | Antigens, CD | 1 | 2015 | 521 | 0.100 |
Why?
| | Overweight | 1 | 2017 | 558 | 0.100 |
Why?
| | Travel | 2 | 2024 | 130 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1079 | 0.100 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 77 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 515 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1313 | 0.090 |
Why?
| | Hemorrhage | 1 | 2016 | 722 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 399 | 0.090 |
Why?
| | School Health Services | 1 | 2014 | 238 | 0.090 |
Why?
| | Papillomavirus Infections | 1 | 2015 | 325 | 0.090 |
Why?
| | Rural Population | 3 | 2022 | 563 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2021 | 556 | 0.090 |
Why?
| | Abortion Applicants | 1 | 2010 | 2 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2019 | 1000 | 0.090 |
Why?
| | Glucose Tolerance Test | 2 | 2013 | 366 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 486 | 0.090 |
Why?
| | Odds Ratio | 2 | 2016 | 1070 | 0.090 |
Why?
| | Health Care Costs | 1 | 2014 | 398 | 0.080 |
Why?
| | Blood Loss, Surgical | 3 | 2016 | 101 | 0.080 |
Why?
| | Anal Canal | 2 | 2022 | 97 | 0.080 |
Why?
| | Domestic Violence | 1 | 2010 | 53 | 0.080 |
Why?
| | Clinical Clerkship | 1 | 2011 | 101 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 601 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 985 | 0.080 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 510 | 0.080 |
Why?
| | Linear Models | 3 | 2019 | 849 | 0.080 |
Why?
| | Preoperative Care | 3 | 2017 | 362 | 0.080 |
Why?
| | Risk Assessment | 4 | 2016 | 3457 | 0.080 |
Why?
| | Misoprostol | 1 | 2009 | 17 | 0.080 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2009 | 21 | 0.080 |
Why?
| | Latin America | 1 | 2009 | 93 | 0.080 |
Why?
| | Sleep | 1 | 2015 | 755 | 0.080 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 63 | 0.080 |
Why?
| | Referral and Consultation | 2 | 2018 | 786 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.080 |
Why?
| | Personality Inventory | 1 | 2009 | 139 | 0.080 |
Why?
| | Interferon-beta | 2 | 2000 | 92 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2009 | 96 | 0.070 |
Why?
| | Dominance, Cerebral | 2 | 2000 | 54 | 0.070 |
Why?
| | Case-Control Studies | 5 | 2020 | 3556 | 0.070 |
Why?
| | Nausea | 2 | 2019 | 111 | 0.070 |
Why?
| | Menarche | 1 | 2008 | 60 | 0.070 |
Why?
| | Sex Factors | 6 | 2020 | 2071 | 0.070 |
Why?
| | Temporal Lobe | 3 | 1997 | 91 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2012 | 578 | 0.070 |
Why?
| | Weight Loss | 2 | 2017 | 787 | 0.070 |
Why?
| | Breast Feeding | 1 | 2012 | 440 | 0.070 |
Why?
| | Schizophrenia, Paranoid | 2 | 1997 | 9 | 0.070 |
Why?
| | Psychotic Disorders | 2 | 2000 | 170 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1627 | 0.070 |
Why?
| | Comorbidity | 2 | 2016 | 1622 | 0.070 |
Why?
| | Reference Values | 3 | 2018 | 816 | 0.070 |
Why?
| | Societies, Medical | 3 | 2018 | 820 | 0.070 |
Why?
| | Students, Health Occupations | 1 | 2007 | 34 | 0.070 |
Why?
| | Healthy Volunteers | 2 | 2019 | 199 | 0.060 |
Why?
| | Fathers | 1 | 2006 | 50 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2006 | 115 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 528 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.060 |
Why?
| | Science | 1 | 2007 | 53 | 0.060 |
Why?
| | Auditory Cortex | 2 | 1997 | 42 | 0.060 |
Why?
| | Prognosis | 4 | 2018 | 4030 | 0.060 |
Why?
| | Azithromycin | 1 | 2006 | 100 | 0.060 |
Why?
| | Urethritis | 1 | 2005 | 5 | 0.060 |
Why?
| | Uterine Cervical Diseases | 1 | 2005 | 6 | 0.060 |
Why?
| | Maternal Health Services | 1 | 2007 | 98 | 0.060 |
Why?
| | Prevalence | 2 | 2017 | 2734 | 0.060 |
Why?
| | Length of Stay | 3 | 2015 | 1215 | 0.060 |
Why?
| | Self Efficacy | 2 | 2019 | 396 | 0.060 |
Why?
| | Fatty Liver | 1 | 2008 | 243 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 1998 | 2253 | 0.060 |
Why?
| | Teaching | 1 | 2007 | 224 | 0.060 |
Why?
| | Chronic Disease | 2 | 2024 | 1793 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 354 | 0.050 |
Why?
| | Metformin | 1 | 2008 | 331 | 0.050 |
Why?
| | Herb-Drug Interactions | 1 | 2023 | 4 | 0.050 |
Why?
| | Acanthosis Nigricans | 1 | 2003 | 6 | 0.050 |
Why?
| | Texas | 1 | 2024 | 244 | 0.050 |
Why?
| | Hospitals, University | 2 | 2016 | 182 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1236 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1483 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1276 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2023 | 6 | 0.050 |
Why?
| | Ovulation | 1 | 2023 | 40 | 0.050 |
Why?
| | Urban Population | 2 | 2016 | 479 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 898 | 0.050 |
Why?
| | Rifampin | 1 | 2023 | 84 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2526 | 0.050 |
Why?
| | Episiotomy | 1 | 2022 | 3 | 0.050 |
Why?
| | Diet | 2 | 2024 | 1278 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2844 | 0.050 |
Why?
| | Anxiety | 2 | 2019 | 1035 | 0.050 |
Why?
| | Pregnancy, Twin | 1 | 2021 | 19 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2022 | 133 | 0.050 |
Why?
| | Neoplasms | 1 | 2016 | 2671 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1809 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.040 |
Why?
| | Alpha Rhythm | 1 | 2000 | 8 | 0.040 |
Why?
| | Reproduction | 1 | 2022 | 204 | 0.040 |
Why?
| | Biomedical Research | 1 | 2007 | 692 | 0.040 |
Why?
| | Wrist | 1 | 2021 | 54 | 0.040 |
Why?
| | Time-to-Pregnancy | 1 | 2020 | 5 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| | Analysis of Variance | 5 | 2005 | 1316 | 0.040 |
Why?
| | Coitus | 2 | 2011 | 22 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2019 | 20 | 0.040 |
Why?
| | Mother-Child Relations | 1 | 2021 | 137 | 0.040 |
Why?
| | Refractory Period, Electrophysiological | 1 | 1999 | 5 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 84 | 0.040 |
Why?
| | Needs Assessment | 2 | 2015 | 376 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2019 | 25 | 0.040 |
Why?
| | Poverty | 2 | 2017 | 521 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 63 | 0.040 |
Why?
| | Median Nerve | 1 | 1999 | 24 | 0.040 |
Why?
| | Electroencephalography | 2 | 1999 | 423 | 0.040 |
Why?
| | Ethics, Institutional | 1 | 2019 | 5 | 0.040 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2000 | 76 | 0.040 |
Why?
| | Visible Human Projects | 1 | 2019 | 2 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2023 | 3284 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2000 | 169 | 0.040 |
Why?
| | Genital Diseases, Female | 1 | 2019 | 28 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 3958 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 425 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 35 | 0.040 |
Why?
| | Reproductive Health Services | 1 | 2019 | 19 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 42 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 226 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 148 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2008 | 1291 | 0.040 |
Why?
| | Operative Time | 1 | 2019 | 145 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 73 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2018 | 21 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 409 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.040 |
Why?
| | Morning Sickness | 1 | 2018 | 2 | 0.040 |
Why?
| | Electric Stimulation | 1 | 1999 | 264 | 0.040 |
Why?
| | Midazolam | 1 | 2018 | 56 | 0.040 |
Why?
| | Memory | 2 | 1999 | 248 | 0.040 |
Why?
| | Psychology, Adolescent | 2 | 2008 | 66 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1946 | 0.040 |
Why?
| | Patient Care | 1 | 2019 | 111 | 0.040 |
Why?
| | Carmustine | 1 | 1998 | 50 | 0.040 |
Why?
| | Frozen Sections | 1 | 2018 | 26 | 0.040 |
Why?
| | Thalamus | 1 | 1999 | 107 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2000 | 250 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1502 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1998 | 79 | 0.030 |
Why?
| | Creatine | 1 | 1998 | 57 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.030 |
Why?
| | Fentanyl | 1 | 2018 | 94 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 167 | 0.030 |
Why?
| | Legislation, Drug | 1 | 2018 | 80 | 0.030 |
Why?
| | Hippocampus | 2 | 2001 | 895 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2019 | 230 | 0.030 |
Why?
| | Hysterosalpingography | 1 | 2017 | 6 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1998 | 247 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 404 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2017 | 16 | 0.030 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2129 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1719 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1325 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 514 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1998 | 389 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 11 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 521 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 120 | 0.030 |
Why?
| | Self Care | 1 | 2019 | 380 | 0.030 |
Why?
| | Marijuana Abuse | 1 | 2019 | 233 | 0.030 |
Why?
| | Cisplatin | 1 | 1998 | 320 | 0.030 |
Why?
| | Medical Audit | 1 | 2016 | 78 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 118 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 121 | 0.030 |
Why?
| | Radiotherapy | 1 | 2016 | 201 | 0.030 |
Why?
| | Terminal Care | 1 | 2019 | 232 | 0.030 |
Why?
| | Patient Simulation | 1 | 2015 | 37 | 0.030 |
Why?
| | Reaction Time | 4 | 2000 | 412 | 0.030 |
Why?
| | Brain Injuries | 1 | 2001 | 494 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 176 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 12 | 0.030 |
Why?
| | North America | 1 | 2016 | 313 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 324 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 21 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 643 | 0.030 |
Why?
| | Income | 1 | 2016 | 202 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 530 | 0.030 |
Why?
| | Competitive Behavior | 1 | 2015 | 43 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 7 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 179 | 0.030 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 27 | 0.030 |
Why?
| | Natural Family Planning Methods | 1 | 2014 | 3 | 0.030 |
Why?
| | Memory Disorders | 1 | 1996 | 164 | 0.030 |
Why?
| | Laparoscopy | 1 | 2019 | 466 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 324 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 150 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 32 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 138 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1995 | 184 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 61 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 261 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2828 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 102 | 0.030 |
Why?
| | Vagina | 1 | 2016 | 187 | 0.030 |
Why?
| | Hemostatics | 1 | 2014 | 52 | 0.030 |
Why?
| | Acoustic Stimulation | 3 | 2000 | 312 | 0.030 |
Why?
| | Personnel Selection | 1 | 2015 | 78 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2016 | 259 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 283 | 0.030 |
Why?
| | Cesarean Section | 1 | 2015 | 184 | 0.030 |
Why?
| | Administration, Intravaginal | 1 | 2013 | 16 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 350 | 0.030 |
Why?
| | Drainage | 1 | 2014 | 173 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1509 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2757 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1998 | 2057 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 786 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2189 | 0.030 |
Why?
| | Child Development | 1 | 1998 | 475 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 436 | 0.020 |
Why?
| | Insulin | 1 | 2003 | 2409 | 0.020 |
Why?
| | Patient Readmission | 1 | 2018 | 697 | 0.020 |
Why?
| | Alcoholism | 1 | 1999 | 807 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 565 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1998 | 455 | 0.020 |
Why?
| | Text Messaging | 1 | 2014 | 157 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1998 | 622 | 0.020 |
Why?
| | Perception | 1 | 2015 | 359 | 0.020 |
Why?
| | Escherichia coli | 1 | 2016 | 815 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4149 | 0.020 |
Why?
| | Specialty Boards | 1 | 2011 | 36 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.020 |
Why?
| | Phenotype | 1 | 1999 | 3196 | 0.020 |
Why?
| | Faculty | 1 | 2011 | 147 | 0.020 |
Why?
| | Medicaid | 1 | 2014 | 435 | 0.020 |
Why?
| | Interferon beta-1a | 2 | 2000 | 12 | 0.020 |
Why?
| | New York City | 1 | 2009 | 85 | 0.020 |
Why?
| | Physicians | 1 | 2018 | 910 | 0.020 |
Why?
| | Urban Health Services | 1 | 2009 | 63 | 0.020 |
Why?
| | Students | 1 | 2014 | 622 | 0.020 |
Why?
| | Gravidity | 1 | 2008 | 6 | 0.020 |
Why?
| | Injections, Intramuscular | 2 | 2000 | 129 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 897 | 0.020 |
Why?
| | Southwestern United States | 1 | 2008 | 91 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 786 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2892 | 0.020 |
Why?
| | Cross-Cultural Comparison | 1 | 2008 | 86 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3412 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1864 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2008 | 203 | 0.020 |
Why?
| | Puberty | 1 | 2008 | 146 | 0.020 |
Why?
| | Urine | 1 | 2007 | 59 | 0.020 |
Why?
| | Medical Indigency | 1 | 2006 | 11 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 77 | 0.020 |
Why?
| | Social Perception | 1 | 2008 | 108 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 389 | 0.020 |
Why?
| | Education | 1 | 2007 | 108 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2553 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 128 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2008 | 273 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11074 | 0.020 |
Why?
| | Social Environment | 1 | 2008 | 296 | 0.020 |
Why?
| | Research Support as Topic | 1 | 2007 | 119 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 2199 | 0.020 |
Why?
| | Triglycerides | 1 | 2008 | 524 | 0.010 |
Why?
| | Universities | 1 | 2007 | 433 | 0.010 |
Why?
| | Attention | 2 | 1999 | 427 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2691 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 42 | 0.010 |
Why?
| | Sex Characteristics | 2 | 1999 | 762 | 0.010 |
Why?
| | Self Concept | 1 | 2005 | 253 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2005 | 363 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1266 | 0.010 |
Why?
| | Research | 1 | 2005 | 451 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 2 | 1997 | 752 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1786 | 0.010 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 25 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 1999 | 94 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1998 | 54 | 0.010 |
Why?
| | Blood Glucose | 1 | 2008 | 2186 | 0.010 |
Why?
| | Sound Localization | 1 | 1998 | 58 | 0.010 |
Why?
| | Gadolinium | 1 | 1998 | 82 | 0.010 |
Why?
| | Cognition | 1 | 2005 | 1153 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 267 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 1995 | 79 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1996 | 329 | 0.010 |
Why?
| | Verbal Behavior | 1 | 1995 | 40 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 565 | 0.010 |
Why?
| | Cognition Disorders | 1 | 1999 | 496 | 0.010 |
Why?
| | Space Perception | 1 | 1995 | 80 | 0.010 |
Why?
| | Recurrence | 1 | 1998 | 1060 | 0.010 |
Why?
| | Software | 1 | 1999 | 665 | 0.010 |
Why?
|
|
Sheeder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|